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ABSTRACT
LINE-1 retrotransposons are abundant repetitive
elements of viral origin, which in normal cells are
kept quiescent through epigenetic mechanisms.
Activation of LINE-1 occurs frequently in cancer
and can enable LINE-1 mobilization but also has
retrotransposition-independent consequences. We
previously reported that in cancer, aberrantly active
LINE-1 promoters can drive transcription of flanking
unique sequences giving rise to LINE-1 chimeric
transcripts (LCTs). Here, we show that one such
LCT, LCT13, is a large transcript (>300kb) running
antisense to the metastasis-suppressor gene TFPI-
2. We have modelled antisense RNA expression at
TFPI-2 in transgenic mouse embryonic stem (ES)
cells and demonstrate that antisense RNA induces
silencing and deposition of repressive histone modi-
fications implying a causal link. Consistent with this,
LCT13 expression in breast and colon cancer cell
lines is associated with silencing and repressive
chromatin at TFPI-2. Furthermore, we detected
LCT13 transcripts in 56% of colorectal tumours ex-
hibiting reduced TFPI-2 expression. Our findings im-
plicate activation of LINE-1 elements in subsequent
epigenetic remodelling of surrounding genes, thus
hinting a novel retrotransposition-independent role
for LINE-1 elements in malignancy.
INTRODUCTION
Tumourigenesis is accompanied by multiple genetic and
epigenetic changes that promote cell proliferation and
escape from growth arrest (1). Epigenetic alterations
include disruption of DNA methylation patterns,
changes in histone modiﬁcations and nucleosome pos-
itioning, ultimately contributing to modiﬁed gene expres-
sion (2). Changes to DNA methylation in cancer are well
characterized, with both genome-wide hypomethylation
at repetitive sequences such as retrotransposons and
hypermethylation of CpG island (CGI) genes present
within the same malignant cell type (3,4). The molecular
mechanisms underlying these epigenetic aberrancies
remain elusive; but it is possible that a relationship exists
between genome-wide changes in DNA modiﬁcations and
alterations in gene expression (4–7).
Decreased methylation of LINE-1 (L1) retroelements is
frequently observed in cancer (8), and examples of direct
correlations between the degree of hypomethylation
and the severity of the disease have been shown (9).
Commensurate with this, hypomethylation-induced
activation of L1s has been proposed to promote cancer
progression and genomic instability (10–12) due to
retrotransposition events (13–15), and indeed, recent
evidence conﬁrms the presence of new somatic L1 inser-
tions in the tumours of patients with lung and colon
cancer (16,17).
A role in genomic instability and chromosomal re-
arrangements is apparent when considering evolutionary
young and intact L1 elements; however, the majority of L1
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elements are older and retrotransposition deﬁcient due to
truncations or accumulated mutations (18). There are ap-
proximately 500 000 truncated L1 copies in the human
genome and about 7000 potential full-length copies; the
majority of which have accumulated mutations that
prevent them from active retrotransposition while retain-
ing intact promoter sequences (18,19). Therefore, several
retrotransposition incompetent elements remain capable
of transcription, and there is evidence that this may con-
tribute to the transcriptome of mammalian cells (20).
L1 promoters are bidirectional, containing a sense
promoter responsible for transcription within the L1
element and an antisense promoter (L1-ASP) that can
drive transcription of adjacent regions giving rise to tran-
scripts composed partly of L1 and partly of genomic
sequence (LINE-1 chimeric transcripts [LCTs]) (21,22).
It is recognized that cancers have a high degree of
hypomethylation at repetitive elements (23–25) and that
L1s can promote transcription of cellular genes as a con-
sequence of ASP activity (21,26,27). Recent evidence
suggests the existence of a causal link between aberrant
activation of individual L1-ASP promoters and cancer
development and progression. For example, the
hypomethylated L1-ASP of an intronic LINE-1 has been
shown to act as an alternative promoter driving expression
of a truncated isoform of the oncogene cMET (28–30).
Our group has also shown that hypomethylation-
induced activation of L1-ASP promoters can drive
transcription of cancer-speciﬁc LCTs transcribed in the
same (sense) or opposite (antisense) orientation with
respect to neighbouring genes (22). Interestingly, the
majority of naturally occurring non-coding antisense tran-
scripts, which can have both activating and silencing
effects (31), have been found to initiate at transposable
elements (26) suggesting an additional mechanism by
which LCTs could affect gene expression. However,
given the abundance of L1 elements within the genome,
the full extent to which aberrant transcriptional activation
of L1 promoters occurs and its relevance to cancer devel-
opment and progression are not thoroughly understood.
Here, we aimed to determine whether aberrant activation
of L1-ASP has the potential to trigger epigenetic silencing
of linked cancer genes through mechanisms similar to
those previously described for antisense RNAs in normal
development and disease (32–35).
MATERIALS AND METHODS
Ethics statement
Ethical approval for the study was obtained from the
Derbyshire Research Ethics Committee to collect colorec-
tal tumour and matched normal tissue from patients who
underwent surgical cancer resection at the Royal Derby
Hospital, Derby, UK.
Tissue samples
All breast samples in this study were purchased from AMS
biotechnology and Ambion. Matched normal and tumour
colorectal tissues were donated by consenting patients
undergoing surgical cancer resection at the Royal Derby
Hospital, Derby, UK.
Cell culture
All cell lines used in the study were validated by STR
proﬁling (Biosynthesys, USA).
MCF-7, HCC-1954, and T47D cell lines were grown in
RPMI 1640 medium and HCT116 and CaCo-2 in
Modiﬁed Eagle’s Media (MEM) and Dulbecco’s
Modiﬁed Eagle Medium (DMEM), respectively (Gibco,
Invitrogen). All cultures were supplemented with 10%
foetal bovine serum and 100 mg/ml penicillin-streptomycin
(Gibco, Invitrogen) and incubated at 37C with 5% CO2.
The polymerase chain reaction (PCR) primers and
reaction conditions used for the study are described in
Supplementary Data, Tables S1–S5.
Strand-speciﬁc RT–PCR
Total RNA was extracted from cells using Total RNA
Isolation reagent (Sigma) and was treated with DNaseI
(Invitrogen). Reverse transcription reactions on 1 mg of
DNaseI-treated total RNA were performed using super-
script II (Invitrogen). PCR reactions were performed on
1 ml of ﬁrst-strand cDNA by mixing 1 Thermo Pol Taq
buffer (New England Biolabs), 0.2mM dNTPs
(Amersham), 0.25mM forward primer, 0.25mM reverse
primer, and 1.25 U Taq polymerase (New England
Biolabs) and incubated at 95C for 5min followed by 30
cycles of 95C for 1min, appropriate annealing tempera-
ture for 1min and 72C for 1min with a ﬁnal incubation
at 72C for 10min.
Bisulphite sequencing
One microgram of genomic DNA was digested with an
appropriate restriction enzyme and bisulphite treated as
published (36). Only clones with >99% conversion of
non-CpG cytosines to uracil were used for the analysis.
Analysis of sequencing data was performed using the BiQ
analyser (37).
Real-time RT–PCR
Two microlitres of reverse-transcription (RT) reaction (see
above) was used as a template for real-time PCR using
inventoried Taq Man probes (Applied Biosystems) as per
manufacturer’s recommendations using an ABI 7500 fast
PCR machine. The Taqman probe for LCT13b was
designed using ABI software and custom made.
Expression data were analysed using GraphPad Prism 5.
30 RACE
Total RNA was reverse transcribed as described using
oligo AUAP-dT (an oligodT primer containing the
AUAP adaptor sequence at its 50 end) to prime the reac-
tions. Two rounds of nested PCR were performed using
primer AUAP in combination with primer 0118 or 0124
for primary and secondary PCR, respectively. PCR
products were cloned using the pGEM-T Easy vector
system (Promega), and Sanger sequencing was outsourced
to Source Biosciences.
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Generation of constructs and ES cell clones
For pTFPI-2as and pTFPI-2pa constructs, a 4.93-kb
human genomic DNA fragment including the full-length
TFPI-2 gene obtained by long-range PCR (Expand Long
PCR kit, Roche) on human genomic DNA with primers
HC63f and HC63g and was cloned into the BamHI and
KpnI sites of pcDNA3 (Invitrogen) and pcDNA3p(A)for,
respectively. pcDNA3p(A)for was derived from pcDNA3
by cloning a 262 bp BGHp(A) fragment, obtained by PCR
on pcDNA3 with primers Hind-p(A)-for and Hind-p(A)-
rev, into the HindIII site of pcDNA3. Prior to electropor-
ation constructs were linearized with ScaI.
E14Tg2a ES cells were maintained undifferentiated
in gelatin-treated ﬂasks in High Glucose DMEM
(Invitrogen) supplemented with 103U/ml leukaemia in-
hibitory factor (LIF; Esgro, Millipore), 18% foetal calf
serum (SLI), 10 mM b-mercaptoethanol (Sigma) and 1
each of sodium pyruvate and non-essential amino acids
(Invitrogen). Stable ES cell clones were obtained by elec-
troporation of 1–2 107 ES cells with 50 mg of puriﬁed
linearized construct fragment containing the neomycin re-
sistance gene. G418-resistant colonies were analysed by
PCR for construct integration. ES cells differentiation
was carried out as previously described (34).
Chromatin immunoprecipitation
Soluble chromatin from mouse ES cells was isolated using
micrococcal nuclease as described (38). Native chromatin
immunoprecipitations were carried out on chromatin pre-
cleared in Protein G sepharose (GE Healthcare) in block
buffer (0.5% BSA in PBS) following published protocols
(39) with Protein G pre-bound antibodies (5–10mg):
&nbsp;a-H3K9me3 (Abcam #8898), aH4K20me3
(Abcam #9053) and rabbit IgG serum (Santa Cruz
Biotechnology) as control. Immunoprecipitated DNA
was puriﬁed using QiaQuick columns (Qiagen). quantita-
tive PCR (qPCR) was performed using Roche multiprobe
with primer pairs in the CGI and intron 2 of TFPI-2, and
normalized to ActB.
Chromatin immunoprecipitations (ChIPs) for cancer
cell lines were performed on 0.4% formaldehyde X-
linked chromatin using the EZ-Magna ChIP A kit
(Millipore) according to manufacturer’s recommendations
using the following antibodies: a-H3K9me3 (Diagenode
pAb-056-050), a-H4K20me3 (Diagenode pAb-057-050),
a-H3K27me3 (Diagenode pAb-069-050), a-H3K4me3
(Diagenode pAb-003-050) and the rabbit IgG provided.
qPCR was performed using custom Taqman assays for
TFPI-2prom, TFPI-2ex2 and APRT 30UTR. For the
GAPDH promoter, primers were provided with the
EZ-Magna ChIP A kit and used with PowerSYBR (AB).
Primers used for qPCR are listed in Supplementary
Tables S4 and S5.
Statistics
Statistical analyses were performed with the GraphPad
software using the Wilcoxon matched-pair signed rank
test.
RESULTS
Expression of LCT13 correlates with presence of TFPI-2
antisense transcripts and TFPI-2 downregulation
In a previous screen for L1 chimeric transcripts, we
identiﬁed a partial transcript, LCT13, present in breast
and colon cancer but not in normal samples from the
same tissue. LCT13 initiates at the ASP of a full-length,
intergenic L1PA2 on chromosome 7 (Figure 1) (22).
Annotation in the GRCh37/hg19 release of the human gen-
ome reveals an SVA_D element insertion within ORF2
rendering the L1 retrotransposition incompetent,
however, maintaining an intact promoter (Supplementary
Figure S1). In addition to LCT13, there are three spliced
expressed sequence tags (ESTs) mapping to this locus
(BG432114 from kidney; DW466562 and DW435092
from liver), which overlap with LCT13 in the 50 region
derived from the L1 element. Two of these ESTs,
BG432114 and DW466562, contain exons in the GNGT1
gene located about 300 kb telomeric to LCT13, and a
putative alternative transcript spanning the locus has
been annotated (GNGT1-005 ID: ENST00000455502).
Between LCT13 and GNGT1, in the antisense orienta-
tion, lies the tissue factor pathway inhibitor-2 gene (TFPI-
2). The TFPI-2 protein is a protease inhibitor with a role in
extracellular matrix (ECM) remodelling (40).TFPI-2 is fre-
quently silenced in cancer (41) and has been proposed to act
as an anti-metastasis gene as its down-regulation may con-
tribute to pathological processes such as tumour invasion
and metastasis (42,43). Given that antisense transcripts
have been shown to silence genes in diseases including
cancer (34,35) and that EST annotations indicate the po-
tential for large antisense transcripts in this region, we
investigated whether LCT13 transcripts originating at the
L1-ASP could act as antisense transcripts to TFPI-2. Using
strand-speciﬁc RT–PCR, we observed transcription of
TFPI-2 antisense RNAs (TFPI-2as, Figure 1B, upper
panel) in two breast cancer cell lines (MCF-7 and HCC-
1954) previously shown to express LCT13 (22). We also
determined the composite levels ofTFPI-2 sense expression
compared to normal breast tissue by real-time RT–PCR
(Figure 1B, lower panel). Expression of TFPI-2as
correlated with decreased levels of TFPI-2 expression in
both cell lines, while normal breast, which had no detect-
able TFPI-2as, expressed high levels of TFPI-2 (Figure 1B,
upper versus lower panel). Similarly, analysis of total RNA
from breast cancer and matched adjacent normal tissue
from ﬁve individuals revealed the presence of TFPI-2as
transcripts in two tumours (Figure 1C, upper panel; T1
and T3) that we have previously shown to express LCT13
(22), and in these cases, reduced TFPI-2 expression was
also observed (Figure 1C, lower panel). Downregulation
of TFPI-2 was also found in a third patient (patient 4)
without any detectable LCT13 and TFPI-2as expression,
a ﬁnding likely to reﬂect multiple mechanisms leading to
loss of expression of this gene in cancer (41). The two re-
maining patients (patients 2 and 5) expressed low levels of
TFPI-2 RNA in the normal tissue with no further decrease
in the tumour consistent with the lack of LCT13 expres-
sion. Our data show that in both cell lines and primary
breast cancers, there is an association between LCT13
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and TFPI-2as expression that correlates with down-
regulation of TFPI-2.
LCT13 is a large RNA transcript including TFPI-2as
Given the potential for large transcripts across this locus
and the restriction of LCT13 and TFPI-2as to the same
cells, we hypothesized that the L1-ASP-driven LCT13 is a
long transcript that extends over the entire locus including
TFPI-2as. To investigate whether LCT13 and TFPI-2as
are part of the same transcriptional unit, we ﬁrst
determined the extent of transcription in the same direc-
tion by examining seven different locations in the 300-kb
region between LCT13 and TFPI-2as in normal breast
and breast cancer cell lines (HCC-1954 and MCF-7) by
strand-speciﬁc RT–PCR (Figure 2A). We conﬁrmed that
transcription of LCT13 and TFPI-2as (regions 2 and 7,
respectively) is unique to the cancer cell lines and that no
transcription in this orientation was detected centromeric
to the L1PA2 associated with LCT13, consistent with
our earlier ﬁnding that LCT13 transcription initiates
at the L1-ASP (22). Indeed, detection of transcription
both immediately upstream and downstream (regions
5 and 6) of the only other L1 element with an intact
promoter in this region (L1PA6 in Figures 1A and 2B)
suggests that this element is not driving the observed tran-
scription of TFPI-2as. In all the additional regions tested
(regions 3–6), we were able to detect strand-speciﬁc
intergenic transcription that is restricted to cancer cells;
hence, intergenic transcription centromeric to TFPI-2as
extends over 300 kb up to the LINE-1 element at
which LCT13 originates and is restricted to the cancer
cell lines in which TFPI-2as is present. This is consist-
ent with ENCODE RNA-seq data from MCF-7 cells
showing a large RNA in this region (Supplementary
Figure S2).
Figure 1. Correlated expression of LCT13 and TFPI-2as transcripts in breast cancer cells. (A) Schematic diagram of a 300-kb region of chromosome
7q21.3 including LCT13 and the TFPI-2 gene. Scale is kilobase and indicates the position from the centromere with the value of 0 arbitrarily
assigned to the TSS of CALCR. Genes (50 segment of CALCR, TFPI-2 and GNGT1) are indicated as gray arrows. Two LINE-1 elements are present
in the region (L1PA2 and L1PA6). Transcriptional orientations are indicated by arrows. LCT13 is a previously identiﬁed transcript shown to initiate
at an L1ASP by 50 RACE (22). TFPI-2as is the fragment analysed by strand-speciﬁc RT–PCR to test for the presence of TFPI-2 antisense RNAs.
Displayed are the three spliced ESTs isolated from kidney (BG432114) and liver (DW466562 and DW435092) libraries that initiate at the LINE1
antisense promoter like LCT13 and extend past the TFPI-2 gene with a putative alternative transcript GNGT1-005 also annotated. (B) Expression of
TFPI-2as (upper) and TFPI-2 (lower) in normal breast (N) and in breast cancer cell lines (H, HCC-1954; M, MCF7) analysed by strand speciﬁc and
real-time RT–PCR, respectively. TFPI-2 expression is reduced in both breast cancer cell lines compared to normal controls (n=3). TFPI-2
expression levels were normalized to HPRT. (C) Expression of TFPI-2as (upper) and TFPI-2 (lower) in a panel of ﬁve matched normal and
tumour breast tissue analysed as described in B.
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To further test the hypothesis that LCT13 drives
transcription of TFPI-2as, we used nucleofection to intro-
duce either a pool of three short interfering RNAs directed
to the unique sequence of LCT13 or the corres-
ponding control scrambled RNAs into MCF-7 cells.
Semiquantitative RT–PCR analysis of LCT13 and
TFPI-2as expression revealed that, relative to control
cells, LCT13 transcript levels were decreased by approxi-
mately 50% in cells transfected with siRNAs to LCT13;
this was paralleled by a 40–50% reduction in the level of
TFPI-2as (Figure 2B). These ﬁndings and our observation
of transcription across this locus, taken together with the
annotated spliced ESTs, support the possibility that
LCT13 and TFPI-2as belong to the same large RNA
transcript.
Alternatively it is also feasible that LCT13 and TFPI-
2as are separate transcripts and transcription of LCT13
promotes that of TFPI-2as by opening up the region as
documented during recombination at immunoglobulin
genes (44). To gain more conclusive evidence, we per-
formed 30 RACE on oligo-dT primed cDNA from
normal breast, MCF-7 and HCC-1954 cells. We identiﬁed
two spliced transcripts (hereafter referred to as LCT13a
and LCT13b) speciﬁc to cancer cells (Figure 3B). These
are partial spliced transcripts arising from dT priming
within polyA tracts present in the genome, and both
display coding potential (Supplementary Figures S3 and
S4). We found that LCT13b contains splicing from the
L1ASP to exon2 and 3 of the GNGT1 gene, thus encom-
passing TFPI-2 in the antisense orientation, conﬁrming
that LCT13 and TFPI-2as are part of the same transcrip-
tional unit. Therefore, this cancer cell–speciﬁc transcript
initiates at an L1-ASP and extends uninterrupted over
more than 300 kb across the genomic locus to generate a
large RNA antisense to TFPI-2.
Antisense RNA can establish silencing at TFPI-2
in mouse embryonic stem cells
We wanted to investigate whether antisense RNAs can
lead to the establishment of silencing at TFPI-2. To this
aim, we utilized a transgenic mouse ES cell system, a well-
established model for the investigation of antisense RNA
and transcription in epigenetic gene silencing (34,35,45).
We generated lines stably transfected with one of two con-
structs: pTFPI-2as, containing the full-length TFPI-2
gene, including promoter and poly-A signals (46), with
antisense transcription driven by the cytomegalovirus
promoter or pTFPI-2pa, a control construct, identical to
pTFPI-2as except for the introduction of the BGH poly-A
signal to prevent antisense transcription through the
TFPI-2 gene (Figure 4A). The CMV promoter was
chosen because it allows stable expression of transgenes
in mouse ES cells (47) and has been used in these cells to
study the functional role of antisense RNA at the p15 gene
in cancer (35). To favour integration of the construct
within permissive chromatin, the neomycin resistance
Figure 2. LCT13 and TFPI-2as expression is linked. (A) Schematic diagram of the genomic region in Figure 1A indicating regions (1–7) analysed by
strand-speciﬁc RT–PCR (middle). Shown above and below the schematic are the ethidium bromide–stained gels used to visualize the strand-speciﬁc
RT–PCR. Regions 2–7 are speciﬁcally expressed in cancer cell lines (H, HCC-1954 and M, MCF-7), but not normal breast (N), showing that cancer-
speciﬁc antisense transcription is detectable up to 300 kb away from the TFPI-2 gene and up to the LINE-1 retrotransposon associated with LCT13.
(B) siRNA knockdown of the LCT13 transcript. 2D densitometry of semiquantitative strand-speciﬁc RT–PCR analysis normalized to APRT control
reveals an approximate 50% knockdown in LCT13 levels in cells transfected with a pool of three siRNA duplexes directed against LCT13 compared
to those transfected with scrambled control siRNAs (left panel). This is paralleled by a 40–50% decrease in the TFPI-2as transcript (right panel).
Nucleic Acids Research, 2013, Vol. 41, No. 14 6861
gene driven by the SV40 promoter was included in the
fragment used for electroporation (Figure 4A), and selec-
tion was maintained throughout the experiment.
We found that in cell lines expressing TFPI-2as RNA
(L2 and L12), TFPI-2 was repressed, while cell lines with
the pTFPI-2pa construct (L7 and L9) and relatively low
levels of antisense transcript expressed higher levels of
TFPI-2, conﬁrming that antisense RNA can directly
induce TFPI-2 gene silencing in this model (Figure 4B).
These results are consistent with previous observations
that randomly integrated constructs with convergent tran-
scription reproducibly display transcriptional silencing
(34,35).
It has been proposed that antisense RNA can drive gene
silencing by triggering the deposition of repressive histone
marks (35,48); therefore, we looked for differences in
histone modiﬁcations in ES cells with and without the
antisense RNA. We observed that decreased TFPI-2 ex-
pression corresponds to a relative increase in H3K9me3
and a marked increase in H4K20me3 within the TFPI-2
CGI in mouse ES cells expressing the antisense RNA
(pTFPI-2as line L2) compared to control cells with low
levels of antisense RNA (pTFPI-2pa line L9) (Figure 4C).
Similar to previous observations (35), the changes in
histone modiﬁcation seem to be the primary consequence
of antisense RNA-mediated silencing in this model system,
with DNA methylation being induced at the silenced locus
on differentiation. Indeed, using bisulphite sequencing, we
could not detect any changes in DNA methylation at the
TFPI-2 promoter in ES cells, which were virtually devoid
of methylation, but DNA methylation was only evident in
day 7 embryoid bodies derived from the pTFPI-2as lines
(Supplementary Figure S5). Therefore, in this model
system, expression of an antisense RNA to TFPI-2 can
induce gene repression via deposition of repressive
histone marks, indicating that the TFPI-2 promoter is sus-
ceptible to this form of silencing.
LCT13 expression is linked to silencing of TFPI-2 in
breast cancer cell lines
We wanted to explore whether cancer cell lines expressing
LCT13 have changes in histone modiﬁcations paralleling
those in the ES cell model. First, to examine TFPI-2 anti-
sense transcription in a more quantitative fashion, we
designed a real-time assay probe spanning the exon1–
exon2 boundary of LCT13b (real-time probe in
Figure 3B). As TFPI-2 lies within intron 1 of LCT13b
(Figure 3A), we reasoned that analysis of expression of
LCT13b could act as a good proxy for the detection of
antisense transcription through TFPI-2. We validated this
assay on random primed RNA from breast cancer cell
lines and normal human mammary epithelial cells
(HMECs) (Supplementary Figure S6) conﬁrming our
earlier observations (Figure 1B) that increased antisense
expression in breast cancer cell lines MCF-7 and HCC-
1954 is associated with decreased TFPI-2 expression,
proving its validity. Moreover we were able to extend
these ﬁndings to an additional breast cancer cell line,
Figure 3. LCT13 and TFPI-2as are part of the same large transcript. Schematic diagram of the 7q21.3 region described in Figure 1A with annotated
LCT13 splicing isoforms LCT13a and LCT13b isolated speciﬁcally from cancer cells by 30 RACE anchored on LCT13. The combined ESTs
described in Figure 1A are shown above for comparison purposes. Note that the LCT13b isoform includes exons 2 and 3 of the GNGT1 gene,
encompassing TFPI-2, consistent with the presence of uninterrupted transcription across this region in cancer cell lines. Below this is a drawing of the
custom Taqman assay designed to study LCT13b expression. The probe spans the splice site between the L1PA2 LINE-1ASP and GNGT1 exon 2.
Spliced LCT13b and real time probe are not drawn to scale.
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T47D, and normal HMEC cells. We found that T47D
expresses LCT13 at very high levels but no detectable
TFPI-2 expression while LCT13 is not present in
HMEC, which express higher levels of TFPI-2
(Supplementary Figure S6).
We examined two regions of the TFPI-2 gene CGI in the
promoter (prom in Figure 5A) and spanning the exon–
intron boundary of exon2 (ex-in2 in Figure 5A) by chro-
matin immunoprecipitation in LCT13 expressing MCF-7
and T47D cells. Antibodies against the active histone modi-
ﬁcation H3K4me3 and the repressive histone modiﬁcations
H3K9me3, H3K27me3 and H4K20me3 were tested.
Enrichment in H3K27me3 and H4K20me3 was observed
at both positions in MCF7 cells (Figure 5B, top panel). A
more marked increase in H4K20me3 and comparable
increase in H3K27me3 were observed in T47D cells at
both positions (Figure 5B, bottom panel) suggesting that
this region is associated with heterochromatic marks in
both cell lines. This is consistent with data available from
the ENCODE project that also shows differences in the
levels of the heterochromatic mark H3K27me3 between
normal cells (HMEC), which are devoid of this mark and
MCF-7 cancer cells that display H3K27me3 enrichment at
TFPI-2 (Supplementary Figure S7).
We examined the methylation status of a segment of the
TFPI-2 CGI spanning the proximal promoter, the tran-
scription start site (TSS), exon 1 and part of intron 1
(Methylation in Figure 5A), in normal breast tissue,
MCF-7 and T47D breast cancer cells. Bisulphite
sequencing reveals that methylation levels in MCF-7
breast cancer cells were negligible and comparable to
those of normal breast (0.47 and 0% methylation, respect-
ively; Figure 5C). In contrast, high levels of DNA methy-
lation (96.6%) were observed in the T47D cell line
(Figure 5C), indicating that repression of TFPI-2
mediated by expression of the long LCT13 RNA in
breast cancer cells can in some instances lead to subse-
quent methylation of the TFPI-2 CGI, which may reﬂect
dissimilarities in differentiation potential between the
MCF-7 and T47D cell lines. Consistent with this, the
Figure 4. A human TFPI-2 transgene is sensitive to antisense RNA repression in mouse ES cells. (A) Schematic diagram of constructs introduced
into mouse ES cells: pTFPI-2as is designed to transcribe antisense to TFPI-2 from a CMV promoter, while pTFPI-2pa has a poly-A signal insertion
downstream of the CMV promoter to block antisense transcription. Arrows indicate direction of transcription. Regions analysed by ChIP are
annotated as ‘prom’ and ‘ex-in2’. (B) Strand-speciﬁc RT–PCR analysis of TFPI-2 antisenese (TFPI-2as) expression in transgenic mouse ES cell lines
demonstrates increased levels in pTFPI-2as lines (L2 and L12) relative to pTFPI-2pa cells (L7 and L9), mouse Aprt acts as a positive control for
RNA quality and quantity. This correlates with a reduction in TFPI-2 expression as shown by real-time PCR normalized to mouse Gapdh. (C) ChIP
analysis followed by real-time PCR. Left panel: Antibodies to H3K9me3 reveal localized enrichment of H3K9me3 in the promoter region in the
antisense expressing cell line, pTFPI-2as (L2), compared to cells transfected with pTFPI-2pa (L9), which express low levels of TFPI-2as. Right panel:
Antibodies to H4K20me3 also show enrichment at the TFPI-2 promoter in pTFPI-2as compared to pTFPI-2pa.
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presence of signiﬁcant H3K4me3 and H3K27me3 at the
TFPI-2 promoter in MCF-7 cells suggests that repression
of TFPI-2 is marked by bivalent histone modiﬁcations
similar to those observed in pluripotent cells. Indeed,
this is conﬁrmed by analysis of available ENCODE
datasets revealing bivalency at the TFPI-2 promoter in
MCF-7 cells (Supplementary Data, Figure S7). This
bivalency is resolved in T47D cells, where H3K4me3 is
reduced but there is now DNA methylation (as observed
in differentiated ES cells), which is incompatible with
H3K4me3 (49).
Taken together our data suggest that LCT13 may
induce TFPI-2 repression by triggering changes in
chromatin conformation via deposition of epigenetic
modiﬁcations in MCF-7 and T47D cells.
LCT13 is not required for maintenance of TFPI-2
silencing in MCF-7 cells
We next wanted to gain further experimental insights
into the involvement of LCT13 in repression of
TFPI-2. To investigate whether expression of the large
antisense transcript is required to maintain TFPI-2
silencing in MCF-7 cells, we analysed LCT13b and
TFPI-2 expression by real-time RT–PCR in MCF-7
cells treated with a pool of three short interfering
RNAs directed to the unique sequence of LCT13 as
described above (Figure 2B and siRNAs in Figure 6A).
Treatment with siRNAs resulted in a 5.5-fold reduction
in LCT13b expression relative to control cells treated
with siRNAs to the equivalent scrambled sequence
(Figure 6B); however, no signiﬁcant increase in TFPI-2
expression was observed in cells treated with the LCT13
siRNA pools relative to scrambled control treated cells
(Figure 6C). These results suggest that LCT13 antisense
RNA is not required to maintain silencing of TFPI-2 in
MCF-7 cells; a ﬁnding similar to antisense-mediated re-
pression at p15 (35).
Given the potential for the formation of double-
stranded RNAs at this locus, we looked for the
presence of small RNAs in LCT13 expressing breast
Figure 5. Silencing of TFPI-2 in breast cancer. (A) Top panel: Schematic diagram of the TFPI-2 gene. Black boxes on the line represent exons of
TFPI-2, and the bent arrow indicates the TSS. Light grey boxes labelled ChIP and methylation denote regions of the TFPI-2 CpG island analysed by
ChIP and bisulphite sequencing, respectively. (B) ChIP assays in MCF-7 (top) and T47D (bottom) cells using antibodies against repressive histone
marks H3K9me3, H3K27me3, H4K20me3, and active marks AcH3 and H3K4me3. Enrichment of H3K27me3 and H4K20me3 is seen in both cell
lines at the TFPI-2 regions tested. (C) Bisulphite sequencing of DNA from normal breast, MCF-7 and T47D cells, shows that the TFPI-2 region
studied is devoid of methylation in normal breast (0%) and MCF-7 cells (0.4%) but heavily methylated in T47D cells (96%). TSS indicates the
transcriptional start site of the TFPI-2 gene; ﬁlled and open circles represent methylated and unmethylated CpG dinucleotides, respectively. Each row
represents an independent clone.
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cancer cells by northern blot analysis (Supplementary
Data, Figure S8). Despite readily detecting a control
small RNA, we were unable to identify any small
RNAs derived from this region. Given that convergent
transcription has been shown to induce transcriptional
gene silencing in a Dicer-dependent manner via produc-
tion of double-stranded RNAs (50), it is possible that
siRNAs may play a role in the establishment but not
the maintenance of silencing, consistent with our
previous ﬁnding that maintenance of silencing
at TFPI-2 is independent of the antisense-RNA
(Figure 6C). Alternatively these data could point to a
Dicer-independent mechanism of antisense-RNA–
mediated repression as suggested at the p15 locus (35)
or indicate that antisense transcription rather than the
antisense RNA is required for the establishment of
silencing, similar to observations at the Igf2R locus
(51). Future experiments will determine what is respon-
sible for TFPI-2 silencing in this system, whether anti-
sense transcription or the antisense-RNA and, if the
latter, whether Dicer is involved.
LCT13 expression is linked to silencing of TFPI-2 in
colorectal cancer
We have previously shown that expression of LCT13 is
not restricted to breast cancer but is also detected in
colon cancer cell lines (22). By using the LCT13b
Taqman assay, we analysed HCT116 and CaCo-2 colon
cancer cells and found that expression of LCT13b is also
associated with down-regulation of TFPI-2 in these lines
(Supplementary Data, Figure S9). In LCT13b expressing
HCT116 and CaCo-2 cells, the TFPI-2 promoter is
enriched in repressive histone modiﬁcations (H3K27me3
and H4K20me3) (Figure 7A). For both HCT116 and
CaCo-2 cells, there was no signiﬁcant enrichment in
H3K4me3 at the TFPI-2 promoter. Indeed, ChIP data
available from ENCODE for these colon cancer cells is
consistent with our ﬁndings (Supplementary Figure S7).
Due to restrictions in our ethical approval, we are unable
to perform ChIP experiments on normal colon tissue;
however, ChIP data on normal colon mucosa available
from the Roadmap Epigenomics Project reveals no sig-
niﬁcant enrichment in repressive modiﬁcations at the
TFPI-2 promoter in normal colon (Supplementary
Figure S10). Furthermore, like T47D, the colon cancer
cell lines tested also lack H3K4me3 and are heavily
methylated (Figure 7B). Taken together, these observa-
tions suggest that antisense-driven silencing of TFPI-2 is
not restricted to breast cancer and may also occur in
colon cancer.
To investigate the in vivo relevance of such ﬁndings, we
analysed LCT13b and TFPI-2 expression levels by real-
time RT–PCR in matched normal and tumour colorectal
tissue samples from 27 sporadic cases of colorectal cancer.
Fifteen of twenty-seven patients (56%) displayed signiﬁ-
cant downregulation of TFPI-2 in tumours (P< 0.0001,
Wilcoxon matched-pairs signed rank test). Of these
patients with downregulated TFPI-2, there is an associ-
ation with a signiﬁcant increase in LCT13b RNA levels
(P=0.0059, Wilcoxon matched-pairs signed rank test)
(Figure 7C). This ﬁnding is consistent with our earlier
observation in a smaller cohort of breast cancer samples
(Figure 1C) and indicates that in a signiﬁcant proportion
of the colorectal cancer cases with TFPI-2 silencing, there
is an association with expression of the antisense RNA
LCT13.
Figure 6. LCT13 is not required for maintenance of silencing at TFPI-2. (A) Schematic diagram of the 7q21.3 region described in Figure 1A drawn
to scale (bar is 40 kb) with the LCT13b transcript and the site targeted by the three independent siRNAs annotated. (B) Expression of LCT13 and
(C) expression of TFPI-2 in MCF-7 cells treated with a pool of three LCT13 siRNAs or the equivalent scrambled control show that decreased
LCT13b levels do not correspond to an increase in TFPI-2 in these cells.
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DISCUSSION
TFPI-2 is a Kunitz-type serine protease inhibitor homolo-
gous to tissue factor pathway inhibitor (TFPI) (52,53),
and its down-regulation in cancer has been proposed to
contribute to tumour malignancy due its role in ECM
remodelling. This is supported by the observation that
decreased levels of TFPI-2 associate with increased
tumour invasion and metastasis in a number of cancers,
particularly more aggressive cancers such as glioma (42)
and pancreatic cancer (42,43). Consistently, ectopic ex-
pression of TFPI-2 can inhibit tumour growth and metas-
tasis in vivo by regulating pericellular ECM remodelling
and angiogenesis (54).
Different molecular mechanisms can lead to loss of
TFPI-2 expression in cancer, including deletions, muta-
tions in the promoter (41) and epigenetic silencing (55),
and recent evidence indicates that TFPI-2 can also be
downregulated by miR-616 in prostate cancer (56). In
this study, we propose an additional mechanism for
TFPI-2 repression in cancer: expression of an aberrant
transcript, LCT13, initiating at the ASP of an intergenic
LINE-1 element and extending over 300 kb, antisense to
the TFPI-2 gene, is associated with TFPI-2 repression and
the deposition of repressive histone marks. Indeed recent
evidence suggests a role for antisense RNA in the targeting
of polycomb repressor complexes (57). Future work will
determine whether such complexes are involved this case.
Interestingly, depending on the cell type, antisense expres-
sion was associated with either a methylated or
unmethylated CGI indicating that methylation of the
CGI is not essential for repression. This result is consistent
with previous ﬁndings that TFPI-2 silencing can occur
without changes in DNA methylation within the
Figure 7. Silencing of TFPI-2 in colorectal cancer. (A) Chromatin immunoprecipitation assays in HCT116 (top) and CaCo-2 (bottom) cells using
antibodies against active histone marks AcH3, H3K4me3, and repressive histone marks H3K9me3, H3K27me3, and H4K20me3 indicate enrichment
of repressive marks H3K27me3 and H4K20me3 at the TFPI-2 regions tested (see Figure 5A). (B) Bisulphite sequencing analysis of 10 independent
clones from normal colon and HCT116 and CaCo-2 colon cancer cells shows that the TFPI-2 region studied is hypomethylated in normal colon
(8.14% methylation) and hypermethylated in HCT116 and CaCo-2 cells (89.07 and 94.1% methylation, respectively). TSS indicates the transcrip-
tional start site of the TFPI-2 gene; ﬁlled and open circles represent methylated and unmethylated CpG dinucleotides, respectively. Each row
represents an independent clone. The region analysed by bisulphite sequencing is depicted in Figure 5A. (C) Analysis of LCT13 and TFPI-2
expression in matched normal and tumour tissues from sporadic cases of colorectal cancer shows an inverse relationship with a signiﬁcant
increase in LCT13 (P< 0.007, Wilcoxon test, n=15) corresponding to a signiﬁcant decrease in TFPI-2 in tumours. Real-time RT–PCR expression
data was normalized to PGK1, GAPDH, and HPRT using GenEx software (Multid Analyses AB).
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proximal promoter region (55). For example, compared to
matched normal liver, human hepatocellular carcinomas
(HCC) signiﬁcantly underexpress TFPI-2 in approxi-
mately 90% of cases; however, more than 50% of HCCs
retain a non-methylated promoter (58). Our DNA methy-
lation ﬁndings are in line with the fact that decreased
LINE-1 methylation does not appear to correlate with
hypermethylation of gene promoter CGIs (59) and may
signify that DNA methylation is an indirect consequence
of the epigenetic silencing brought about by the repressive
histone modiﬁcations; supported by our ES cell data and
published work on antisense RNA-mediated silencing of
p15 in cancer (35). The heterogeneous patterns of DNA
methylation may reﬂect cellular origin as has been previ-
ously observed in cancer (6,7), and their functional impact
is a subject of intense interest and speculation.
Given the repetitive nature of LINE-1 elements within
the genome, this mechanism may be more widespread and
not restricted to TFPI-2. Antisense RNAs have been pre-
viously observed to silence genes (34,35) and transposable
elements are the source of the majority of non-coding anti-
sense transcripts (26). In this context, it is tempting to
speculate that LINE-1 driven transcripts are implicated
in some instances of long-range silencing reported in
cancer (60), pointing to a novel retrotransposition inde-
pendent role for LINE-1 activation in cancer. An
intragenic L1-ASP has been shown to act as an alternate
promoter in cancer driving the transcription of a truncated
and oncogenic isoform of the c-MET gene (28,30,61), and
the ability of retrotransposons to act as alternative pro-
moters for protein coding genes has been reported (20).
Indeed, the LCT13 L1ASP could potentially act as an al-
ternative promoter for GNGT1 (Supplementary Data,
Figures S3 and S4), but further work is necessary to
conﬁrm whether LCT13b is polyadenylated and
translated. Nevertheless our data show that LCT13 acts
as an antisense RNA linked to TFPI-2 downregulation
indicating that L1-derived transcripts can affect gene ex-
pression patterns in cancer by multiple mechanisms.
In conclusion, activation of a LINE-1 element and
silencing of a tumour suppressor gene may be causally
linked events in cancer, suggesting a widespread mechan-
ism, whereby aberrantly active LINE-1 promoters drive
RNA transcription over long distances and trigger epigen-
etic silencing of protective genes; thus promoting cancer
progression. What triggers activation of LINE-1 pro-
moters in cancer remains a fundamental and unanswered
question. It is widely believed that LINE-1 activation is a
consequence of genome-wide hypomethylation observed
in cancer, and indeed methylation has been proposed as
a defence mechanism against transposable elements (62).
However, the mechanisms leading to genome-wide
hypomethylation are unclear and also whether the same
mechanisms are responsible for activation of transposition
proﬁcient and deﬁcient LINE-1 elements is still not
known. Further studies exploiting LCTs like LCT13 will
make addressing these questions possible by studying in-
dividual LINE-1 promoters. Finally, it is worth noting
that as the majority of non-coding RNAs initiate at
retrotransposable elements (26), LINE-1 retrotrans-
poson-driven transcription may play important regulatory
roles in normal development and differentiation at stages
and in tissues where LINE-1 elements are active (e.g. germ
cells, embryonic stem cells and pre-implantation stages)
(63). Therefore, the LINE-1-driven epigenetic effects
described in our article maybe more widespread than pre-
viously thought and as relevant to normal development
and differentiation as to disease progression.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1–5, Supplementary Figures 1–10,
Supplementary Method and Supplementary References
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